362 related articles for article (PubMed ID: 26147141)
1. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients.
Costa C; Balloco C; Sidoti F; Mantovani S; Rittà M; Piceghello A; Fop F; Messina M; Cavallo R
J Clin Virol; 2014 Dec; 61(4):523-8. PubMed ID: 25453571
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
Costa C; Astegiano S; Terlizzi ME; Sidoti F; Curtoni A; Solidoro P; Baldi S; Bergallo M; Cavallo R
Transplant Proc; 2011 May; 43(4):1159-61. PubMed ID: 21620077
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
[TBL] [Abstract][Full Text] [Related]
9. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
Chiereghin A; Gabrielli L; Zanfi C; Petrisli E; Lauro A; Piccirilli G; Baccolini F; Dazzi A; Cescon M; Morelli MC; Pinna AD; Landini MP; Lazzarotto T
Transplant Proc; 2010; 42(1):69-73. PubMed ID: 20172283
[TBL] [Abstract][Full Text] [Related]
10. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
11. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
[TBL] [Abstract][Full Text] [Related]
12. Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice.
Solidoro P; Patrucco F; Boffini M; Rinaldi M; Airoldi C; Costa C; Cavallo R; Albera C
Ther Adv Respir Dis; 2020; 14():1753466620981851. PubMed ID: 33356914
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
14. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplant cytomegalovirus immunoglobulin G antibody levels could prevent severe cytomegalovirus infections post-transplant in liver transplant recipients: Experience from a tertiary care liver centre.
Gupta E; Pamecha V; Verma Y; Kumar N; Rastogi A; Hasnian N; Bhadoria AS
Indian J Med Microbiol; 2017; 35(4):499-503. PubMed ID: 29405140
[TBL] [Abstract][Full Text] [Related]
16. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
Chanouzas D; Small A; Borrows R; Ball S
PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study.
Kim SH; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Han DJ
Infect Chemother; 2015 Jun; 47(2):105-10. PubMed ID: 26157588
[TBL] [Abstract][Full Text] [Related]
19. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
Molina-Ortega A; Martín-Gandul C; Mena-Romo JD; Rodríguez-Hernández MJ; Suñer M; Bernal C; Sánchez M; Sánchez-Céspedes J; Pérez Romero P; Cordero E
Clin Microbiol Infect; 2019 Jun; 25(6):753-758. PubMed ID: 30292792
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]